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ABSTRACT 38 
Background: Currently, the biological diagnosis of Pneumocystis jirovecii pneumonia PjP 39 
infection usually relies on microbiological investigations in bronchial-alveolar lavage fluid 40 
(BALF) by conventional staining methods and/or molecular biology. However, bronchial-41 
alveolar lavage is sometimes complicated to manage, especially in weakened patients. 42 
Therefore, alternative clinical samples – easier to collect – are warranted in such specific 43 
contexts. Objective: Over a four year-period, diagnostic performance of an original method 44 
based on combination of quantitative real-time polymerase chain reaction (qPCR) in 45 
nasopharyngeal aspirate (NPA) with measurement of β-(1, 3)-D-glucan antigen (BDG) in 46 
serum was prospectively assessed in a single center. Patients/methods: Results were compared 47 
with those obtained in BALF through direct staining methods and qPCR. True-positives were 48 
defined by an independent committee based on clinical, radiological, and biological data. 49 
Overall, 48 individuals with a definitive diagnosis of PjP infection were included, and 48 50 
controls were selected upon matching for age, sex and underlying disease(s). Results: qPCR 51 
results were strongly correlated between BALF and NPA (P<0.0001). Altogether, greater 52 
diagnostic performance was achieved when establishing the positive cutoff of BDG antigen at 53 
143 pg/mL. In such conditions, sensitivity of the testing based on either positive BDG 54 
measurement or positive qPCR in NPA was then calculated at 93.75%, 95%CI [82.37 – 55 
98.40%], and specificity at 97.87%, 95%CI [87.66 – 100.00%]. Conclusions: Further validation 56 
through multicenter studies is now required, especially for establishing clear cutoffs. However, 57 
one could already state that combination of qPCR in the NPA with BDG measurement in 58 
serum may be a valuable substitute for BALF examination.  59 
  60 
Keywords: Uvitex; calcofluor-blue; fungal infection; virus; respiratory samples. 61 
62 
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INTRODUCTION  63 
Pneumocystis jirovecii is an airborne fungus which is responsible for interstitial pneumonia in 64 
humans 
1,2
, referred to as PjP (Pneumocystis jirovecii pneumonia) and formerly as PCP 65 
(Pneumocystis carinii – ancient taxonomic name of the pathogen – pneumonia). PjP infection 66 
occurs mostly in immunocompromised patients, such as subjects infected with human 67 
immunodeficiency virus (HIV or those suffering from hematological malignancies 3,4. It has 68 
been also largely described in solid-organ transplant recipients or in individuals receiving 69 
immunosuppressive therapy for autoimmune or inflammatory diseases 
5
. Clinical signs of PjP 70 
infection are not specific; they include fever, thoracic pain and cough, and they can 71 
misleadingly mimic other lung infections, mostly those caused by viruses 
2,4
.  72 
Because P. jirovecii is not easy to grow in vitro 
6
, the biological diagnosis of PjP remains 73 
complex 
7
, and is usually based on direct observation of the fungus and/or detection of its 74 
DNA in respiratory fluids 
2,7,8
. Since P. jirovecii thrives at the surface of type I-pneumocyte 75 
cells in the lung alveoli 
9
, bronchial-alveolar lavage fluid (BALF) is primarily acknowledged 76 
as the gold-standard clinical sample 
7
. However, one can argue that bronchial-alveolar lavage 77 
(BAL) is a somewhat invasive procedure, and can be complex to manage, especially in 78 
weakened patients. Moreover, there is currently a relevant trend promoting easy collection of 79 
clinical specimens from the upper respiratory tract 
10–12
. Unfortunately, so far, superficial 80 
samples have been shown to be less sensitive for the diagnosis of PjP infection, especially 81 
because the fungal burden seems too low inside. Thus, May-Grünwald Giemsa MGG or 82 
Gomori-Grocott’s methenamine silver (GMS) staining, as well as commercial kits using 83 
monoclonal and fluorescent-conjugated antibodies (IFA, for immunofluorescent assay 84 
allowing detection of P. jirovecii cysts (asci)), have never provided reliable results 
13,14
: for 85 
example in HIV-positive patients, only 55.3% sputa were found positive by direct methods 86 
during true PjP infection 
15
. Eventually, only quantitative real-time polymerase chain reaction 87 
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(qPCR appears to be powerful enough to detect efficiently P. jirovecii DNA in upper 88 
respiratory samples, but, for technical reasons, is not easily feasible in viscous respiratory 89 
specimens like sputa. Likewise, its diagnostic performance remains somewhat questionable 90 
when considered alone 
10
, as it displays real limitations for distinguishing between casual 91 
carriage and true infection 
8
. Therefore in upper respiratory samples, qPCR was demonstrated 92 
efficient for the microbiological diagnosis in only 48.0% children 
10
, and in 66.2% HIV-93 
positive adult patients 
15
. It should also be noted that some surrogate biomarkers have been 94 
recently developed, such as the measurement of β-(1,3)-D-glucan (BDG) antigen in serum. 95 
Nonetheless, the latter lacks specificity when used alone 
16,17
, because BDG is a pan-fungal 96 
cell wall compound which is actually commonly found in most of fungi. Furthermore, the 97 
positive cutoff recommended by the manufacturer at 80 picogram per milliliter (pg/mL) 98 
appears actually quite low, and thus is thought to expose to a risk of false-positive results. 99 
Altogether in such a context, alternative diagnostic approaches for PjP infection are still 100 
required 
11
, especially in patients who cannot undergo BAL. Detection of viral DNA in 101 
nasopharyngeal aspirate (NPA) samples is now a standardized routine practice in cases of 102 
febrile pneumonia 
18
. NPA specimens are technically-easy to handle in a laboratory, because 103 
they are less viscous than sputa and because several commercial devices and all-inclusive kits 104 
can automatically detect most moieties of the respiratory pathogens in them. However, P. 105 
jirovecii has not been included so far in the panel of the distributed kits 
19
, except for the Fast 106 
Track Diagnostics Respiratory Pathogen 33® kit (Fast Track Diagnostics, Sliema, Malta) 
20
 107 
and one of the High-Plex 24® product for respiratory pathogens involved in pneumonia 108 
(AusDiagnostics, Mascot, Australia).  109 
Therefore in this study, we assessed over a four year-period the diagnostic performance of an 110 
in-house qPCR carried out in NPAs, in combination with measurement of BDG antigen in 111 
serum, for the diagnosis of PjP infection. Results were systematically discussed in light of the 112 
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definitive diagnosis obtained according to the conventional methods, primarily based on 113 
microbiological investigations in BALFs, as well as on radiology findings and clinical signs.  114 
 115 
MATERIAL AND METHODS 116 
Study population  117 
Geographical location 118 
This study was carried out over a four-year period [02-06-2014 – 07-31-2018] in a French 119 
university hospital (lat.: 46.449070 – long.: 6.865345) which hosts 2,008 inpatient beds for 120 
the whole panel of surgical and medical specialties.  121 
 122 
Description of cases 123 
All patients with definitive PjP infection were selected as true cases, as long as they were ≥ 15 124 
years old and if BALF volume was sufficient for conventional investigations. The definitive 125 
diagnosis of PjP infection had been systematically adjudicated by an independent committee 126 
of physicians (radiologists, intensivists, microbiologists, infectious disease specialists, and 127 
pulmonologists) in light of the medical records. The classification was based on agreement of 128 
the microbiological results obtained in BALF (at least one P. jirovecii form by microscopic 129 
method(s) like MGG or calcofluor-blue brightener 
21
, and/or a positive Cq value  35 cycles 130 
by qPCR), in association with consistent clinical examination and suggestive medical imaging 131 
1,7
. For instance in subjects with solid tumours, solid-organ transplantation or hematologic 132 
malignancies receiving long-term high-dose steroids (≥0.3mg/kg/day of prednisone equivalent 133 
for ≥3 weeks) and/or anti-cancer chemotherapy, the following criteria were systematically 134 
searched: subacute fever associated with hypoxemic and diffuse pulmonary involvement (e.g. 135 
bilateral infiltrates and/or ground-glass opacities and/or nodules and/or alveolar condensation 136 
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on high-resolution computed tomography scan 22. For HIV-positive patients, the following 137 
data were specifically screened for: resting oxygen saturation <90% and diffuse radiology 138 
shadowing (e.g. bilateral infiltrates and/or ground-glass opacities and/or nodules and/or cystic 139 
changes on high-resolution computed tomography scan), as well as a history of anti-P. 140 
jirovecii primary chemoprophylaxis 
14
. The independent committee also assessed clinical 141 
outcome after 14 days of anti-P. jirovecii curative treatment. All the cases of PjP infection 142 
were subsequently reported to the French centre of surveillance for fungal diseases (Centre 143 
national de reference des mycoses et antifongiques, Institut Paris, France: 144 
https://www.pasteur.fr/en/institut-pasteur). Finally, only diseased patients who were sampled 145 
for NPA and blood, within three days before or after the BAL, were retained for further 146 
analysis and comparison.  147 
 148 
Selection of controls 149 
Control individuals were selected from patients in the same hospital. Non-inclusion criteria 150 
were similar to those of the cases suffering from PjP infection. Controls were assumed not 151 
infected with P. jirovecii on the basis of the clinical examination, the medical imaging and the 152 
biological tests in BALF 
7
. They were matched with PjP cases for age, sex and underlying 153 
disease(s).  154 
 155 
Measurement of β-(1, 3)-D-glucan antigen in serum 156 
Beta-(1, 3)-D-glucan antigen was tested in each patient serum that had been collected  three 157 
days before or after the BAL, using the Fungitell assay® serum test (Cape Cod, East 158 
Falmouth – MA, U.S.A.) and glucan-free material. Briefly, 5µL serum samples were 159 
dispensed in duplicate into a 96-well Pyroplate® microplate (CapeCod, East Falmouth – MA, 160 
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U.S.A.), and 20µL alkaline pre-treatment solution were then added. After a 30 min- 161 
incubation period at 37°C, 100µL reconstituted Fungitell lysate reagent® were introduced 162 
into each well. Kinetic data were then read with the MultiSkan FC® (Thermofischer 163 
Scientifics, Dardilly, France) over 40 min at 37°C. Measurement of BDG antigen 164 
concentration was calculated for each sample according to the values of calibrated standards. 165 
Positive threshold was established by the manufacturer at 80 pg/mL 
16
. Samples were re-166 
tested in case of discrepancy between the two wells. 167 
 168 
Detection of P. jirovecii DNA in nasopharyngeal aspirates 169 
Practically, NPA was collected  three days before or after the BAL using a standardized 170 
procedure: for each patient, a catheter was inserted into his nostrils as far as the posterior 171 
pharynx, and a mural vacuum pump was used for suction of mucus. Every aspirate specimen 172 
was introduced in a sterile tube using a mucus extractor device. All NPA specimens were first 173 
addressed to the Microbiology laboratory where virus detection for 26 respiratory pathogens 174 
was carried out using routine medical practice with the panel included in the Allplex® 175 
Respiratory Panel Assays kit (Seegene, Seoul, Korea; P. jirovecii is not included in this panel), 176 
and then they were subsequently transferred to the Parasitology-Mycology department 177 
specifically for the purpose of the study.  178 
Detection of a 121 bp fragment of the P. jirovecii repeated mitochondrial large subunit 179 
mtLSU rRNA gene was performed by qPCR 8,21. Briefly, DNA was extracted from 200 µL 180 
of NPA liquid pellet (after centrifugation, 1,730 x g, 10min). The pellet was first incubated in 181 
10µL lyticase 1 IU/µL for 10 min at 37 °C. The DNA was then extracted using 182 
superparamagnetic beads from the MycoGENIE® DNA extraction kit (Ademtech, Pessac, 183 
France), according to the manufacturer’s recommendations. Real-time qPCR was performed 184 
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in a final volume of 25 µL using the GoTaq Probe qPCR Master mix® (Promega, 185 
Charbonnières-les-Bains, France) and 5µL of each DNA extract. The following 186 
oligonucleotides were used: PJF1: 5'-CTGTTTCCCTTTCGACTATCTACCTT-3’ and PJR1: 187 
5'-CACTGAATATCTCGAGGGAGTATGAA-3’ for the primers, and 5’-FAM-188 
TCGCACATAGTCTGATTAT-MGB-3’ for the specific TaqMan® probe 8. The final 189 
concentrations of primers and probe were 0.4 µM. The concentration of MgCl2 was adjusted 190 
to 0.5 mM. Amplifications were performed in duplicate on a LightCycler 480 II® Real-Time 191 
PCR (Roche Applied Science, La Rochelle, France), under the following conditions: initial 192 
decontamination for 2 min at 50 °C, followed by denaturation for 5 min at 95 °C, and then 45 193 
cycles of hybridization/elongation, including 15 s at 95 °C, 1 min at 60°C, and a final cooling 194 
step at 40 °C for 30 s. Inhibition was assessed by an internal control (Universal Inhibition 195 
Control Cy5®, Diagenode Diagnostics, Liège, Belgium) and an endogenous in-house positive 196 
internal control (P. jirovecii DNA extract from the local collection). The results were 197 
expressed in quantitative cycle (Cq) values 
8
.  198 
 199 
Assay performance and analysis 200 
Epidemiological data were provided by the Service d’Information Médicale, Épidémiologie et 201 
Économie de la Santé (SIMEES) from Tours University Hospital. Statistical analyses were 202 
performed using XLStat v.18.06® software (Addinsoft, Paris, France). Missing data were 203 
managed by the method of mean imputation. A true-positive was defined as a positive result 204 
that was in agreement with the definitive diagnosis of PjP infection that had been adjudicated 205 
by the scientific independent committee. Diagnostic measures were calculated to assess 206 
performance: sensitivity (Se), specificity (Sp), predictive values (PPV and NPV), and 207 
likelihood ratios (+LR and -LR), as well as receiver operating characteristic ROC curves 208 
and their respective areas under the curve AUC for measurement of BDG antigen 209 
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concentration and qPCR Cq in NPA. The comparison of diagnostic performance was made 210 
using the paired two-sample Student’s t-test. The Spearman's rank correlation coefficient was 211 
used to assess the correlation of results obtained with the quantitative methods, while the 212 
observer agreement for categorical data was measured through the Cohen’s kappa coefficient 213 
(κ), in light of the interpretation instructions by Landis et Koch  23. The -risk was adjusted at 214 
0.05. 215 
 216 
Ethics 217 
This study was non-interventional, involving no change in standard clinical practices. Only a 218 
form of non-objection was signed by the included patients. Clinical data were anonymized 219 
before analysis. The biological samples were stored in the hospital collection N°DC-20100-220 
1216, approved by the French Ministry of Research. The study registration number 221 
N°2015_030 was issued by the French Data Protection Authority (CNIL, Commission 222 
Nationale de l’Informatique et des Libertés). Final approval N°2015 23 was given by the local 223 
Ethics Committee of Tours University Hospital (Espace de Réflexion Ethique, Région Centre-224 
Val de Loire, France) before submission. The authors complied with the BRISQ guidelines 
24
. 225 
 226 
RESULTS 227 
Description of the study population 228 
Overall, 1,118 distinct patients underwent a BAL during the study period for high suspicion 229 
of PjP infection (Figure 1). Ten and 32 were not included because they were children or the 230 
total volume of the collected BALF was insufficient for investigation. One hundred and 231 
nineteen subjects were eventually adjudicated by the scientific committee as consistent with 232 
PjP infection. Thus, the overall incidence of PjP infection in our university hospital was 233 
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estimated at 2.21 episodes per 1,000 patient-days. Finally, only 48 subjects with PjP infection 234 
were actually sampled for NPA and blood concomitantly to the BALF ± three days, and then 235 
were selected for further analysis. Meanwhile, the NPAs were all tested negative with the 236 
Allplex® Respiratory Panel Assays kit (Seegene, Seoul, Korea). Forty-eight control subjects 237 
were selected upon stringent matching with the PjP cases (Figure 1). 238 
For the cases retained with definitive diagnosis of PjP infection, all the characteristics at 239 
baseline are summarized in Table I and Suppl. Material 1. Most involved 240 
immunocompromised males above 60 years of age (median = 64 years old), with a mean 241 
count of 0.12 G/L CD4+ lymphocytes at the time of diagnosis. Respiratory symptoms and 242 
fever were the major clinical signs. In BALF, microscopic findings (Suppl. Materials 1 et 2) 243 
and qPCR results were concordant, i.e. both positive, in 35 out of the 48 cases (72.92%). 244 
Quantitative PCR appeared insignificantly more performant in BALF than microscopic 245 
observation for the definitive microbiological diagnosis of PjP infection (P=0.26). Calcofluor-246 
blue brightener allowed visual counting 430 ± 280 P. jirovecii asci per glass slide in average 247 
(Suppl. Material 2). Microscopic examination and qPCR in BALF were systematically 248 
negative (with Cq > 35) in all the control subjects (but two qPCR were detected at 39 cycles, 249 
three at 38, three at 37, and two at 36). In the 48 patients with true PjP infection, mean BDG 250 
was measured at 527.63 ± 545.06 pg/mL vs. 70.81 ± 33.98 pg/mL in the controls (P<0.0001) 251 
(Figure 2A). The ROC curve allowed calculation of the BDG cutoff value at 143 pg/mL 252 
(Figure 2B).  253 
 254 
Diagnostic performance of the microbiological testing 255 
Cutoff for qPCR Cq in NPA was calculated at 35.4 cycles (Suppl. Material 3; for more 256 
comfort, value at 35 cycles was retained for further analyses). For every specimen, no 257 
amplification inhibition was noticed. In the 48 controls, all qPCR results were found negative 258 
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in NPA (Cq = 36 cycles or above). In contrast in the 48 cases asserted with PjP infection, 40 259 
were positive (83.33%; mean Cq calculated at 32.21 ± 3.51 cycles; AUC ROC curve = 0.96 ± 260 
0.02; Suppl. Materials 1 et 3), whereas four of them had been negative in BALF. Noteworthy 261 
for two patients, the discrepancies were more questionable (Cq=30.12 cycles in NPA vs. 262 
39.50 in BALF, and 31.60 vs. 40.00, respectively): for the first subject, the BALF was of poor 263 
quality (very viscous) which could maybe hamper the reliability of the diagnosis in it, while 264 
the second patient was already given anti-P.jirovecii therapy at time of sampling that could 265 
perhaps substantially interfere with the fungus detection. However, no significant differences 266 
were observed between the two types of samples (concordance rate = 86.73%; mean Cq = 267 
32.21 vs. 30.43 cycles, respectively; P=0.12): qPCR findings in BALF and in NPA were 268 
statistically correlated (Spearman’s rank correlation coefficient = 0.79, P<0.0001 (Figure 3); 269 
Cohen's kappa coefficient (κ) = 0.77, P<0.0001). In all, sensitivity and specificity of the 270 
qPCR in NPA alone were estimated at 81.25%, 95%CI [67.74 – 89.95%] and 100.00%, 95%CI 271 
[90.75 – 100.00%], respectively, while they were just slightly higher in BALF, at 89.58%, 272 
95%CI [77.26 – 95.81] and 100.00%, 95%CI [90.75 – 100.00]. 273 
When associating the qPCR results in NPA with the BDG measurement in serum, diagnostic 274 
performance of the combined test could vary greatly (Table II). They primarily depended on 275 
the selection of the threshold value for the measurement of BDG antigen: indeed, sensitivity 276 
of BDG alone was 91.67%, 95%CI [79.78 – 97.15%] vs. 85.42%, 95%CI [72.41 – 92.97%] for 277 
the recommended cutoff at 80 pg/mL vs. the calculated cutoff at 143 pg/mL, respectively. 278 
Likewise, specificity shifted from 65.96%, 95%CI [51.59 – 77.82%] to 97.87%, 95%CI [87.66 – 279 
100.00%]. Thus, for combination of qPCR positive in NPA ± BDG measurement > 80 pg/mL, 280 
sensitivity was assessed at 95.83%, 95%CI [85.10 – 99.55%], while specificity plunged to 281 
65.96%, 95%CI [51.59 – 77.82%]. There were two false-negative result (4.17%) amongst the 282 
diseased cases with PjP infection, and 16 false-positive (33.33%) amongst the controls. Based 283 
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on the threshold calculated using the ROC curve, a better diagnostic performance was then 284 
demonstrated: 93.75%, 95%CI [82.37 – 98.40%] for sensitivity, and 97.87%, 95%CI [87.66 – 285 
100.00%] for specificity of the testing associating qPCR positive in NPA ± BDG 286 
measurement > 143 pg/mL. Three false-negative results were reported among the cases with 287 
true PjP infection (6.25%): one in a male patient suffering from chronic lymphocytic 288 
leukemia (who was undergoing anti-P. jirovecii treatment at time of sampling), one in an 289 
individual with solid cancer and for whom the microscopy examination was negative but 290 
qPCR positive in BALF (no mention of any anti-P. jirovecii treatment), and one in a 39-year-291 
old woman with sarcoidosis with direct examination positive but qPCR negative in BALF 292 
(who was undergoing anti-P. jirovecii treatment at time of sampling). Only one false-positive 293 
was recorded among the controls (2.08%), with a BDG antigen measured at 484.0 pg/mL 294 
(whereas the Aspergillus galactomannan antigen was also very elevated in this patient’s 295 
BALF). 296 
 297 
DISCUSSION 298 
Pneumocystis jirovecii pneumonia (PjP, formerly PCP) is a fungal infection with potentially 299 
severe consequences 
1,2
: mortality rates are still estimated at about 20% 
25
. More accurate and 300 
rapid diagnosis would allow a prompter initiation of effective antifungal treatment, therefore, 301 
substantially reducing subsequent complications 
26
. Alternative samples are expected to 302 
circumvent the actual limitations of BAL, which is still nowadays the gold-standard clinical 303 
sampling for diagnosis of PjP infection. For example in the past, induced sputa have been 304 
quite frequently used for such purposes in patients infected with HIV 
13
, although their 305 
induction can provoke nausea and bronchospasm. More recently, NPAs were shown to be 306 
relevant for detection of viral and bacterial DNA, because they are less viscous than sputa and 307 
largely standardized for urgent practice in cases of febrile pneumonia 
18
. Nonetheless, global 308 
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sensitivity of direct methods or qPCR alone was shown to be quite low in all samples from 309 
the upper respiratory tract 
14
, including NPAs 
10
. Therefore in situations when BAL is not 310 
possible, it seems to make sense to combine P. jirovecii DNA detection in NPA 
11
 with 311 
another diagnostic tool, such as the measurement of BDG antigen concentration in serum 
17
. 312 
In this study and in contrast to previous ones 
11
, the initial inclusion criterion was specifically  313 
based on the clinical suspicion of PjP infection in populations at risk. This means that a 314 
prospective analysis of the results in NPAs and BDG was systematically performed in light of 315 
those obtained with the conventional diagnostic methods carried out in BALFs. Nonetheless, 316 
we would like to emphasize herein the pertinence of brainstorming by experts that should be 317 
initiated regarding the value of the positive cutoff for the BDG concentration. Results of BDG 318 
assay are acknowledged to vary substantially; it’s the reason why a “grey zone” should be 319 
recommendable instead of a strict cutoff, like it is currently the case according to the 320 
manufacturer’s instructions. In the present study, we demonstrated that the lower threshold 321 
(established by the kit’s manufacturer) was largely less specific than the higher one 322 
(calculated at 143 pg/mL), while the sensitivities were actually quite close (just slightly better 323 
for the lower cutoff). In the same way, other authors previously suggested to increase the 324 
cutoff value that is usually recommended by the supplier 
27–29
. Regarding the results of P. 325 
jirovecii qPCR in NPAs, no one can argue that the reliability of positive specimens is 326 
debatable, since all enrolled patients were symptomatic with febrile pneumonia at hospital 327 
admission and/or showed suggestive imaging in a suggestive epidemiological context. In 328 
other words, P. jirovecii colonization or casual carriage could be confidently precluded in 329 
them. Furthermore, frequent association of positive qPCR in NPA with BDG concentration ≥ 330 
143 pg/mL undoubtedly reinforced the likelihood of definitive diagnosis of PjP infection. 331 
Likewise, we can assert that association of the two tests provides a comforting backup in case 332 
one of them is found to be negative, especially when clinical signs are obvious and/or medical 333 
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imaging is suggestive. This situation actually occurred in this work in 27.1% of the patients 334 
with definitive diagnosis of PjP infection. In all, thanks to this combined approach, only 4.2% 335 
patients of the whole cohort were misdiagnosed. False-negative results were obtained in HIV-336 
negative patients with cancer or auto-immune disease who are acknowledged to host lower 337 
fungal burden 
21
. Furthermore, two of them were already been given anti-P. jirovecii therapy 338 
at time of diagnosis: we previously demonstrated that antifungal treatment can substantially 339 
reduce the sensitivity of qPCR (while not affecting so much the microscopic approach) 
21
.  340 
One limitation of testing in NPA is that P. jirovecii DNA is probably present in lower 341 
amounts than in BALF (even if correlation of the Cq values between the two types of samples 342 
appeared statistically quite strong herein). Consequently to date, strict quantitative 343 
comparison of Cq and fungal burden remains questionable between the two clinical 344 
specimens, given the heterogeneity of their volumes and their consistency; some were more 345 
liquid, while other were rather mucous. As a result, the Cq thresholds that are usually 346 
expressed in BALF should be applied to NPAs with great caution 
8
, although the cutoff for the 347 
latter was calculated in this study very close to the one recommended so far in BALF. 348 
In conclusion, we propose the following strategy for a convenient diagnostic approach of PjP 349 
infection: as soon as the initial screening has showed BDG antigen concentration ≥ 143 350 
pg/mL in serum of patients at risk, NPA should be in priority investigated if BAL is not 351 
realizable. Positive result of qPCR in NPA is then highly suggestive to support rapid 352 
instauration of anti-P. jirovecii curative therapy. Of course, further validation through wide 353 
multi-center studies is now expected. Besides, our results also suggest that adding P. jirovecii 354 
to all the panels of respiratory microorganisms tested by automated commercial devices 355 
seems to be critical. Globally, this would generate limited additional costs, as all the nucleic 356 
acids are already extracted for the other tests in the panel. 357 
 358 
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FIGURE LEGENDS 462 
Figure 1: Flowchart of the study.  463 
Abbreviations: BALF, bronchial-alveolar lavage fluid; NPA, nasopharyngeal aspirate; PjP, 464 
Pneumocystis jirovecii pneumonia;  matched with cases for age, sex and underlying 465 
disease(s). 466 
 467 
Figure 2: Measurement of β-(1, 3)-D-glucan (BDG) antigen concentration in serum. A – 468 
Box plot showing the difference of BDG concentrations between the true cases of 469 
Pneumocystis jirovecii pneumonia and the controls. In each group, the mean was calculated at 470 
527.6 ± 272.5 pg/mL [30.0 – 3830.0] and 70.9 ± 33.9 pg/mL [15.6 – 484.0], respectively. The 471 
horizontal dotted line N°1 indicates the threshold suggested by the manufacturer at 80 pg/mL. 472 
The dotted line N°2 shows the upper cutoff determined at 143 pg/mL by the receiver 473 
operating characteristic (ROC) curve of the present study. The grey zone is indicated through 474 
hatched space; B – ROC curve of the measurement of BDG antigen concentration in serum. 475 
The area under the curve (AUC) is estimated at 0.92 ± 0.03, 95%CI [0.87 – 0.98]. The grey thin 476 
arrow indicates the cutoff calculated at 143 pg/mL, thus enabling sensitivity at 85.42%, 95%CI 477 
[72.41 – 92.97%], and specificity at 97.87%, 95%CI [87.66 - 100.00%]. 478 
 479 
Figure 3: Comparison of the Cq values between qPCR carried out in bronchial-alveolar 480 
lavage fluids and qPCR in nasopharyngeal aspirates. Results are presented in box plot 481 
showing correlation curve according to Spearman inside a confidence ellipse. All the dots that 482 
appear at Cq = 40 cycles actually correspond to qPCR with no detection of P. jirovecii DNA 483 
(Cq > 40 cycles, i.e. no inflexion of the amplification curve). 484 
● data from control-patients with no diagnosis of P. jirovecii pneumonia  485 
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♦ data from case-patients with diagnosis of P. jirovecii pneumonia. 486 
Abbreviations: Cq, quantitative cycle; qPCR, quantitative real-time polymerase chain reaction. 487 
 488 
Supplementary material 1: Individual details of the case-patients with asserted 489 
Pneumocystis jirovecii pneumonia.  490 
 491 
Supplementary material 2: Example of positive microscopic observation during direct 492 
examination showing Pneumocystis jirovecii cysts (asci) in bronchial-alveolar lavage 493 
fluids, using calcofluor-blue brightener (Fluorescent Brightener 28®, Sigma, Saint-Louis, 494 
MO, U.S.A.), at magnification x1250. Note the specific “coffee-bean” shape of the cyst and 495 
sporadic presence of a halo (example pointed by the thin arrow) 
21
.  496 
 497 
Supplementary material 3: ROC curve of the P. jirovecii qPCR in naso-pharyngeal 498 
aspirates expressed in number of quantitative cycles (Cq). The area under the curve 499 
(AUC) is estimated at 0.96 ± 0.02, 95%CI [0.92 – 1.00]. The grey thin arrow indicates the 500 
cutoff calculated at 35.4 cycles. 501 
